Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 13, 2009, Pages 2209-2220

  Gennari, Luigi ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Estrogen; Lasofoxifene; Menopause; Osteoporosis; SERMS

Indexed keywords

CALCIUM; CHOLESTEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIACYLGLYCEROL; VITAMIN D;

ALTERNATIVE MEDICINE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMUR NECK FRACTURE; FRACTURE; HOT FLUSH; HUMAN; INTESTINE WALL; LEG CRAMP; LOADING DRUG DOSE; LUNG EMBOLISM; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SPINE FRACTURE; STROKE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA SECRETION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ATROPHY; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PYRROLIDINES; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES; VAGINA; VAGINAL DISEASES;

EID: 68949097428     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903127241     Document Type: Review

References (66)

1. Osteoporosis Prevention, Diagnosis, and Therapy Consensus Statement 2000. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001;285:785-795
2. Melton LJ 3rd, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the national osteoporosis foundation. J Bone Miner Res 1997;12:16-23
3. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882 (Pubitemid 29126875)
4. Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin N Am 2006;32:617-629
5. Melton LJ, Atkinson EJ, Cooper C, et al. Vertebral fractures predict subsequent fracture. Osteoporos Int 1999;10:214-221 (Pubitemid 29458716)
6. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75 (Pubitemid 23028113)
7. Hui SL, Slemenda CW, Carey MA, Johnston CC. Choosing between predictors of fractures. J Bone Miner Res 1995;10:1816-1822
8. Sambrock P, Cooper C. Osteoporosis. Lancet 2006;367:2010-2018 Updated review of osteoporosis.
9. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-2261 (Pubitemid 43788139)
10. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest 2005;115:3318-3325
11. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocrinol Rev 2002;23:279-302 (Pubitemid 34651948)
12. Gustafsson JA. Estrogen receptor beta - a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379-383
13. Bord S, Horner A, Beavan S, Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab 2001;86:2309-2314 (Pubitemid 32472956)
14. Pike AC. Lessons learnt from structural studies of the oestrogen receptor. Best Pract Res Clin Endocrinol Metab 2006;20:1-4
15. Bilezikian JP, Matsumoto T, Bellido T, et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 2009;24:373-385 Updated revision of current treatment options for osteoporosis.
16. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941 (Pubitemid 32003509)
17. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
18. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477 (Pubitemid 46556472)
19. Vassilopoulou-Sellin R. Breast cancer and hormonal replacement therapy. Ann NY Acad Sci 2003;997:341-350 (Pubitemid 38491089)
20. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009;122(2 Suppl):S14-21
21. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-818
22. Cho CH, Nuttall ME. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Emerg Drugs 2001;6:137-154
23. Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 2005;96:15-25 Comprehensive up-to-date overview on the pharmacology of SERMs. (Pubitemid 40267682)
24. Riggs BL, Hartmann LC. Selective Estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629 Overview of current knowledge about the mechanism of action of SERMs.
25. Morello KC, Wurz GT, Degregorio MW. SERMs: current status and future trends. Crit Rev Oncol Hematol 2002;43:63-76 (Pubitemid 34722788)
26. Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361-379 (Pubitemid 46790261)
27. Gennari L, Merlotti D, De Paola V, Nuti R. Raloxifene in breast cancer prevention. Expert Opin Drug Saf 2008;7:259-270
28. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Miner Metab 1996;14:1-9
29. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-2202 (Pubitemid 32269244)
30. Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-822 (Pubitemid 37462131)
31. Rosati RL, Da Silva Jardine P, Cameron KO. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998;41:2928-2931
32. Ke HZ, Paralkar VM, Grasser WA. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139:2068-2076
33. Gennari L, Merlotti D, Martini G, Nuti R. Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin Investig Drugs 2006;15:1091-1103 (Pubitemid 44314660)
34. Ke HZ, Qi H, Chidsey-Frink KL, et al. Effects of different dose regimens of lasofoxifene (CP-336,156) in preventing bone loss in ovariectomized rats. J Bone Miner Res 2000;15:S1-310
35. Ke HZ, Foley GL, Simmons HA, et al. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005
36. Cohen LA, Pittman B, Wang CX, et al. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res 2001;61:8683-8688 (Pubitemid 34013877)
37. Yang X, Reinhold AR, Rosati RL, Liu KK. Enzyme-catalyzed asymmetric deacylation for the preparation of lasofoxifene (CP-336156), a selective estrogen receptor modulator. Org Lett 2000;2:4025-4027
38. Gardner M, Nishizawa Y, Wei G, et al. A single-dose pharmacokinetic study of lasofoxifene in Japanese and caucasian postmenopausal women. J Bone Miner Res 2004;19: abstract M469
39. Gardner M, Taylor A, Wei G, et al. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol 2006;46:52-58 (Pubitemid 43021713)
40. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-372 (Pubitemid 36433876)
41. Katzenellenbogen JA. D- 1,2-Dyaril-3,4- dihydronaphthalenes: photofluorogenic ligands for the estrogen receptor. J Steroid Biochem 1985;23:929-937
42. Prakash C, Johnson KA, Gardner MJ. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. Drug Metab Dispos 2008;36:1218-1226 (Pubitemid 351929303)
43. Roman D, Bramson C, Ouellet D, et al. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. J Clin Pharmacol 2005;45:1407-1412 (Pubitemid 41642444)
44. Moller RA, Fisher JM, Taylor AE, et al. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism. Ann Pharmacother 2006;40:32-37
45. Bramson C, Ouellet D, Roman D, et al. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. J Clin Pharmacol 2006;46:29-36 (Pubitemid 43021711)
46. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-386 First clinical trial demonstrating the efficacy of lasofoxifene for the prevention of bone loss in postmenopausal women. (Pubitemid 43918197)
47. Background document for Meeting of Advisory Committee for Reproductive Health Drugs. 8 Sept 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/ 08/ briefing/2008-4381b1-01-FDA.pdf [Last accessed 11 May 2009] Comprehensive overview about clinical efficacy and safety of lasofoxifene on multiple outcomes, emerged from Phase III trials.
48. FABLYN® (lasofoxifene tartrate) 0.5 mg tablets, NDA 22-242, Reproductive Health Drugs Advisory Committee Briefing Document. Available from: http://www. fda.gov/ohrms/dockets/ac/08/ briefing/2008-4381b1-02-Pfizer.pdf [Last accessed 11 May 2009] Comprehensive overview about clinical efficacy and safety of lasofoxifene on multiple outcomes, emerged from Phase III trials.
49. Moller R, Fisher J, Taylor A, et al. Effect of food on the pharmacokinetics of lasofoxifene, in healthy postmenopausal women. J Bone Miner Res 2004;19: abstract SU487
50. Lee A, Radecki D, Wolter K, et al. Lasofoxifene phase 2 and phase 3 clinical trial design and strategy. J Bone Miner Res 2005;20: abstract M384
51. Day W, Martel J, Lee A. Lasofoxifene phase 2 dose response analysis in postmenopausal women. J Bone Miner Res 2005;20: abstract M385
52. Portman DJ, Moffett AH, Bachman GA, et al. Lasofoxifene, a selective estrogen receptor modulator, improves objective measures of vaginal atrophy. Obstet Gynecol 2004;103:25S-6S
53. Ettinger M, Schwartz E, Emkey R, et al. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM) in the prevention of bone loss in postmenopausal women. Presented at the 86th Annual Meeting of the Endocrine Society, 16-19 June 2004, New Orleans, LA, USA
54. McClung M, Omizo M, Weiss S, et al. Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women. J Bone Miner Res 2004;19: abstract SA424
55. McClung M, Portman D, Emkey R, et al. Comparison of the extraskeletal effects of lasofoxifene and raloxifene. J Bone Miner Res 2004;19: abstract SA423
56. McClung M, Siris E, Cummings S, et al. Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. J Bone Miner Res 2005;20: abstract F429
57. Davidson M, Moffett A, Welty F, et al. Extraskeletal Effects of lasofoxifene on postmenopausal women. J Bone Miner Res 2005;20: abstract SA428
58. Eastell R, Reid DM, Vukicevic S, et al. The effects of lasofoxifene on bone turnover markers: the PEARL trial. J Bone Miner Res 2008;23: abstract 1287
59. Glover SJ, Rogers A, Gossiel F, Eastell R. A randomized double blinded controlled trial of individual response in biochemical markers of bone turnover to lasofoxifene therapy. J Bone Miner Res 2008;23: abstract M507
60. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23: abstract 1288
61. European Medicines Agency, Pre-Authorisation Evaluation of Medicines for Human Use. Committee for Medicinal Products for Human Use summary of positive opinion for Fablyn. London, 18 December 2008. Doc.Ref. EMEA/ CHMP/609979/2008
62. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647 First clinical trial demonstrating the efficacy of a SERM for the prevention and treatment of osteoporosis in postmenopausal women.
63. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-1754 (Pubitemid 28492005)
64. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645(Erratum JAMA 1999:282:2124) (Pubitemid 29384151)
65. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-134(Correction in Breast Cancer Res Treat 2001:67) (Pubitemid 32193616)
66. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761 (Pubitemid 39654569)